

10/081961

Search results

Refine Search

Your wildcard search against 10000 terms has yielded the results below.

Your result set for the last L# is incomplete.

The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

Search Results -

Terms	Documents
L7 and interfering near genetic near element\$	0

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L22

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, December 14, 2004 [Printable Copy](#) [Create Case](#)

Set Name	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L22	L7 and interfering near genetic near element\$	0	L22
L21	adenovir\$ near5 vector\$ and (DF3 or steroid) near5 enhancer\$	63	L21
L20	L17 and steroid	0	L20
L19	L17 and DF3	1	L19
L18	L17 and enhancer\$	1	L18
L17	20040241857	1	L17
L16	L14 and enhancer\$	49	L16
L15	L14 an enhancer\$	280921	L15
L14	adenovir\$ near5 vector\$ and CEA and fetoprotein and PSA and probasin	49	L14
L13	adenovir\$ near5 vector\$ and (CEA or fetoprotein or AFP or PSA or p21 or	1364	L13

	probasin) near5 (promoter\$ or transcription\$)		
<u>L12</u>	adenovir\$ near10 ITR\$ near5 nucleotide\$	68	<u>L12</u>
<u>L11</u>	adenovir\$ near10 ITR\$ near5 size	4	<u>L11</u>
<u>L10</u>	L9 and leaky	7	<u>L10</u>
<u>L9</u>	(stop near codon\$ or polyadenylation or polyA or termination) near10 (upstream or "5'") near5 promoter\$ near10 vector\$	449	<u>L9</u>
<u>L8</u>	L7 and insulating near3 sequence\$	1	<u>L8</u>
<u>L7</u>	(stop near codon\$ or polyadenylation or polyA or termination) near10 upstream near5 promoter\$ near10 vector\$	278	<u>L7</u>
<u>L6</u>	(stop near codon\$ or polyadenylation or polyA or termination) near10 upstream near5 promoter\$ near10 adenovir\$	6	<u>L6</u>
<u>L5</u>	(stop near codon\$ or polyadenylation or polyA or termination) near10 upstream near5 promoter\$ near10 E1a	0	<u>L5</u>
<u>L4</u>	(stop near codon\$ or polyadenylation or polyA or termination) near10 upstream near5 promoter\$ near5 E1a	0	<u>L4</u>
<u>L3</u>	L1 and E1a	111	<u>L3</u>
<u>L2</u>	L1 and adenovir\$	647	<u>L2</u>
<u>L1</u>	(stop near codon\$ or polyadenylation or polyA or termination) near10 upstream near5 promoter\$	1144	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 49 of 49 returned.**

-
- ☐ 1. 20040241857. 13 Apr 04. 02 Dec 04. Tissue specific adenoviral vectors. Henderson, Daniel R., et al. 435/456; 424/93.2 435/235.1 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 2. 20040224408. 10 Dec 03. 11 Nov 04. THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation. Girard, Jean-Philippe, et al. 435/455; 514/44 A61K048/00 C12N015/85.
-
- ☐ 3. 20040213764. 26 Mar 04. 28 Oct 04. Adenovirus replication-competent vectors expressing trail. Wold, William, et al. 424/93.2; 435/456 A61K048/00 C12N015/861.
-
- ☐ 4. 20040197770. 13 Nov 03. 07 Oct 04. Induction of apoptosis by HIV-1 infected monocytic cells. Sperber, Kirk, et al. 435/5; C12Q001/70.
-
- ☐ 5. 20040161409. 06 Oct 03. 19 Aug 04. Induction of immune response to antigens expressed by recombinant adeno-associated virus. Kurtzman, Gary J., et al. 424/93.2; 435/456 A61K048/00 C12N015/861.
-
- ☐ 6. 20040146489. 21 Oct 03. 29 Jul 04. Cell-specific adenovirus vectors comprising an internal ribosome entry site. Yu, De-Chao, et al. 424/93.2; 435/235.1 435/456 514/44 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 7. 20040047845. 25 Apr 01. 11 Mar 04. Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2. Watson, Dennis K., et al. 424/93.21; 435/226 435/320.1 435/325 435/69.1 536/23.2 A61K048/00 C07H021/04 C12N009/64.
-
- ☐ 8. 20030223971. 13 Jan 03. 04 Dec 03. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors. Kurtzman, Gary J., et al. 424/93.21; 435/235.1 435/456 514/44 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 9. 20030186337. 10 Dec 02. 02 Oct 03. Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control. Girard, Jean-Philippe, et al. 435/7.23; 435/226 435/320.1 435/325 435/69.1 536/23.2 G01N033/574 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
-
- ☐ 10. 20030152553. 02 May 02. 14 Aug 03. Compositions comprising tissue specific adenoviral vectors. Little, Andrew S., et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 11. 20030148520. 21 Mar 01. 07 Aug 03. Cell-specific adenovirus vectors comprising an internal ribosome entry site. Yu, De-Chao, et al. 435/456; 424/93.2 435/235.1 435/320.1 C12N015/861 C12N007/00 A61K048/00.
-
- ☐ 12. 20030143702. 31 Oct 02. 31 Jul 03. Vesicular monoamine transporter gene therapy in parkinson's disease. Kang, Un Jung. 435/128; 435/325 435/455 435/456 C12P013/00 C12N015/861 C12N015/867 C12N005/06.
-
- ☐ 13. 20030139324. 19 Nov 02. 24 Jul 03. Tumor suppressor designated TS10q23.3. Steck, Peter, et al. 514/2; 435/184 435/320.1 435/325 435/6 435/7.23 536/23.2 A61K038/17 C12Q001/68
-

G01N033/574 C12N009/99 C07H021/04 C12P021/02 C12N005/06.

☐ 14. 20030138412. 27 Jun 02. 24 Jul 03. Inhibition of tumor growth and metastasis by N5 gene. Goodrich, David W., et al. 424/93.21; 435/7.23 514/44 A61K048/00 G01N033/574.

☐ 15. 20030118555. 21 Aug 02. 26 Jun 03. Target cell-specific adenoviral vectors containing E3 and methods of use thereof. Henderson, Daniel R., et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

☐ 16. 20030104624. 22 Feb 02. 05 Jun 03. Novel vector constructs. Clarke, Lori, et al. 435/456; 435/320.1 435/325 C12N015/861 C12N015/74.

☐ 17. 20030082722. 05 Aug 02. 01 May 03. Method for amplifying expression from a cell specific promoter. Fang, Bingliang. 435/69.1; 435/320.1 435/325 435/455 C12P021/02 C12N005/06 C12N015/00.

☐ 18. 20030072758. 21 May 02. 17 Apr 03. BMPR1A involvement in juvenile polyposis. Howe, James R.. 424/155.1; 435/6 435/7.23 C12Q001/68 G01N033/574 A61K039/395.

☐ 19. 20030068307. 21 Mar 01. 10 Apr 03. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation. Yu, De-Chao, et al. 424/93.21; 424/649 424/85.7 514/110 514/12 514/171 514/251 514/263.38 514/27 514/34 514/50 A61K048/00 A61K038/21 A61K031/7048 A61K033/24.

☐ 20. 20030044383. 10 Sep 98. 06 Mar 03. TISSUE SPECIFIC ADENOVIRAL VECTORS. HENDERSON, DANIEL R., et al. 424/93.2; 435/320.1 435/325 435/440 435/455 514/44 A61K048/00 C12P021/02 C12N005/06 C12N015/87.

☐ 21. 20030026792. 23 Oct 01. 06 Feb 03. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof. Lamparski, Henry, et al. 424/93.21; 435/320.1 435/456 A61K048/00 C12N015/861.

☐ 22. 20020182723. 12 Jun 01. 05 Dec 02. AN IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS. Zhang, Shuyuan, et al. 435/320.1; 424/233.1 435/235.1 435/239 536/23.72 536/24.1 C12N007/01 C12N015/861 C07H021/04 A61K039/235.

☐ 23. 20020164799. 02 Jul 01. 07 Nov 02. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof. Little, Andrew S., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/00.

☐ 24. 20020102243. 16 May 01. 01 Aug 02. Induction of immune response to antigens expressed by recombinant adeno-associated virus. Kurtzman, Gary J., et al. 424/93.21; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

☐ 25. 20020081601. 25 Apr 01. 27 Jun 02. Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2. Watson, Dennis K., et al. 435/6; 435/325 514/44 536/23.2 A61K048/00 C12Q001/68 C07H021/04.

☐ 26. 20020068049. 06 Dec 00. 06 Jun 02. Tissue specific adenoviral vectors. Henderson, Daniel R., et al. 424/93.21; 435/235.1 435/320.1 A61K048/00 C12N015/861.

- ☐ 27. 20010053352. 09 Sep 99. 20 Dec 01. ADENOVIRUS VECTORS CONTAINING CELL STATUS-SPECIFIC RESPONSE ELEMENTS AND METHODS OF USE THEREOF. YU, DE CHAO, et al. 424/93.6; 435/320.1 435/69.1 514/44 536/23.5 A61K048/00 C12N015/861 C12P021/02 C07H021/04.

- ☐ 28. 20010036929. 26 Apr 01. 01 Nov 01. Xrcc3 is required for assembly of Rad51-complexes in vivo. Weichselbaum, Ralph R., et al. 514/44; 424/649 514/34 A61K048/00 A61K033/24.

- ☐ 29. 20010011078. 22 Dec 00. 02 Aug 01. DNA fragmentation factor involved in apoptosis. Wang, Xiaodong, et al. 514/44; 424/93.2 424/94.6 435/196 435/320.1 435/6 530/388.26 536/23.2 A61K048/00 C07H021/04 C07K016/40 A61K038/46 C12N009/16 A61K031/713.

- ☐ 30. 6790648. 22 Dec 00; 14 Sep 04. DNA fragmentation factor involved in apoptosis. Wang; Xiaodong, et al. 435/196; 435/252.3 435/320.1 435/69.1 530/300 530/321 530/326 536/23.2. C12N009/22 C12N015/55 C12N014/79 C07K014/435.

- ☐ 31. 6743906. 01 Oct 99; 01 Jun 04. PPP2R1B is a tumor suppressor. Evans; Glen A., et al. 536/23.5; 536/24.1 536/24.2. C07H021/04 A01N043/04.

- ☐ 32. 6737052. 31 Aug 00; 18 May 04. Induction of programmed cell death by N5 gene. Goodrich; David W., et al. 424/93.2; 424/93.21 424/93.6 435/320.1 435/455 435/456. A01N063/00 A61K048/00.

- ☐ 33. 6710036. 16 May 01; 23 Mar 04. Induction of immune response to antigens expressed by recombinant adeno-associated virus. Kurtzman; Gary J., et al. 514/44; 424/93.1 424/93.2 435/320.1 435/325 435/455. A61K048/00 C12N015/63 C12N015/85.

- ☐ 34. 6692736. 21 Mar 01; 17 Feb 04. Cell-specific adenovirus vectors comprising an internal ribosome entry site. Yu; De-Chao, et al. 424/93.2; 435/235.1 435/320.1 435/369 435/375 435/457 435/69.1 435/91.4 435/91.41 435/91.42 514/44. C12P021/06 C12P007/00 C12P015/00 C12N005/10 C12N007/02 C12N015/86.

- ☐ 35. 6676935. 10 Sep 98; 13 Jan 04. Tissue specific adenoviral vectors. Henderson; Daniel R., et al. 424/93.2; 424/93.6 435/320.1 435/325 435/456 514/44. A61K048/00 C12N005/00 C12N015/00.

- ☐ 36. 6585968. 02 Jul 01; 01 Jul 03. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof. Little; Andrew S., et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/325 435/366 435/455 435/456 435/457 435/69.1 536/23.1 536/24.1. A61K048/00 C12N015/861 C12N005/10 C12N015/63 C12N015/64.

- ☐ 37. 6531456. 28 Aug 00; 11 Mar 03. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors. Kurtzman; Gary J., et al. 514/44; 424/199.1 424/93.2 435/235.1 435/320.1 435/455. A61K048/00 A61K031/00 C12N015/63 C12N015/74.

- ☐ 38. 6517828. 26 May 00; 11 Feb 03. C-CAM as an angiogenesis inhibitor. Lin; Sue-Hwa, et al. 424/93.2; 435/320.1 514/44 530/350 536/23.5. C12N015/79 A61K048/00.

- ☐ 39. 6506378. 15 Dec 99; 14 Jan 03. Vesicular monoamine transporter gene therapy in Parkinson's disease. Kang; Un Jung. 424/93.21; 424/93.1 424/93.2 435/320.1 435/325 435/375 435/69.1 514/44 536/23.1 536/23.5. A01N063/00 A01N043/04 A61K048/00 C12N015/00 C12N005/00 C07H021/02 C07H021/04.

- ☐ 40. 6495130. 29 Dec 99; 17 Dec 02. Target cell-specific adenoviral vectors containing E3 and methods of use thereof. Henderson; Daniel R., et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/325 435/455 514/44. A61K353/00 A61K048/00 C12N015/63 C12N015/85 C12N015/09.
-
- ☐ 41. 6482795. 26 Aug 98; 19 Nov 02. Tumor suppressor designated TS10q23.3. Steck; Peter, et al. 514/2; 514/12 514/21 530/350. A61K038/00 A61K038/16 A61K038/17 C07K014/00 C07K014/435.
-
- ☐ 42. 6432700. 02 Mar 98; 13 Aug 02. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same. Henderson; Daniel R., et al. 435/320.1; 424/199.1 424/204.1 424/233.1 424/93.2 424/93.6 435/252.3 514/44 536/23.1 536/23.4 536/23.72 536/24.1. C12N015/00.
-
- ☐ 43. 6423491. 13 May 99; 23 Jul 02. Method of diagnosing juvenile polyposis (JP). Howe; James R., et al. 435/6; 435/4 435/7.1 435/7.21 435/7.23 435/7.92 435/7.95 436/63 436/64. C12Q001/00 C12Q001/68 G01N033/567 G01N033/574 G01N033/53.
-
- ☐ 44. 6420335. 16 Jun 99; 16 Jul 02. Combination of radiotherapy and anti-angiogenic factors. Weichselbaum; Ralph R., et al. 514/2; 378/65 514/1 530/350 600/1. A01N037/18 A01N005/10 A01N061/00 A01N005/00 C07K001/00.
-
- ☐ 45. 6254862. 02 Mar 98; 03 Jul 01. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof. Little; Andrew S., et al. 424/93.2; 424/93.6 435/320.1 435/325 435/366 435/370 435/455 435/456 435/5 435/6. A61K048/00 C12N015/861 C12N005/10 C12N015/63.
-
- ☐ 46. 6242426. 23 Jul 98; 05 Jun 01. Induction of immune response to antigens expressed by recombinant adeno-associated virus. Kurtzman; Gary J., et al. 514/44; 435/320.1 435/325. A61K048/00 C12N015/63 C12N015/85.
-
- ☐ 47. 6218180. 10 Mar 99; 17 Apr 01. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors. Kurtzman; Gary J., et al. 435/320.1; 424/199.1 424/93.2 435/235.1. C12N015/63 C12N007/00 A61K048/00 A61K038/00.
-
- ☐ 48. 6165737. 16 Apr 98; 26 Dec 00. DNA fragmentation factor involved in apoptosis. Wang; Xiaodong, et al. 435/7.6; 435/23 435/252.3 435/252.33 435/320.1 435/7.91 536/23.2. C12Q001/00 C12Q001/37 C12N009/64 C12N015/70 C12N015/74.
-
- ☐ 49. 5952221. 05 Mar 97; 14 Sep 99. Adeno-associated virus vectors comprising a first and second nucleic acid sequence. Kurtzman; Gary J., et al. 435/320.1; 424/93.1 435/325 514/44. C12N015/63 C12N015/85 A61K048/00.
-

[Generate Collection](#)[Print](#)

Terms	Documents
L14 and enhancer\$	49

[Prev Page](#)[Next Page](#)[Go to Doc#](#)